EcoR1 Capital, LLC: ORIC PHARMACEUTICALS INC (ORIC): Quarterly 13F Position History
As of Q1 2026, EcoR1 Capital, LLC reported 6,728,116 shares of ORIC PHARMACEUTICALS INC (ORIC), worth $85.2M and representing 3.6% of its 13F equity book. The position first appeared in Q2 2020 and has been disclosed across 24 13F-HR filings in Pactolio's tracked window.
- 6,728,116Shares Held (Latest Filing)
- $85.2MReported Market Value (Latest Filing)
- 3.6%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$30.2MQuarter-over-Quarter Value Change
- 6,728,116Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 24 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 6,728,116 | 0 | — | $85.2M | 3.6% | $12.7 |
| Q4 2025 | 6,728,116 | 0 | — | $55.0M | 2.5% | $8.2 |
| Q3 2025 | 6,728,116 | +5,110,048 | +315.8% | $80.7M | 3.9% | $12.0 |
| Q2 2025 | 1,618,068 | 1,800,000 | -52.7% | $16.4M | 1.0% | $10.2 |
| Q1 2025 | 3,418,068 | 0 | — | $19.1M | 1.1% | $5.6 |
| Q4 2024 | 3,418,068 | 0 | — | $27.6M | 1.1% | $8.1 |
| Q3 2024 | 3,418,068 | 0 | — | $35.0M | 1.2% | $10.3 |
| Q2 2024 | 3,418,068 | 0 | — | $24.2M | 0.7% | $7.1 |
| Q1 2024 | 3,418,068 | 0 | — | $47.0M | 1.2% | $13.8 |
| Q4 2023 | 3,418,068 | 0 | — | $31.4M | 0.8% | $9.2 |
| Q3 2023 | 3,418,068 | 0 | — | $20.7M | 0.7% | $6.0 |
| Q2 2023 | 3,418,068 | 0 | — | $26.5M | 0.7% | $7.8 |
| Q1 2023 | 3,418,068 | 0 | — | $19.5M | 0.6% | $5.7 |
| Q4 2022 | 3,418,068 | 0 | — | $20.1M | 0.6% | $5.9 |
| Q3 2022 | 3,418,068 | 0 | — | $10.9M | 0.3% | $3.2 |
| Q2 2022 | 3,418,068 | 0 | — | $15.3M | 0.5% | $4.5 |
| Q1 2022 | 3,418,068 | 50,876 | -1.5% | $18.3M | 0.6% | $5.3 |
| Q4 2021 | 3,468,944 | 0 | — | $51.0M | 1.6% | $14.7 |
| Q3 2021 | 3,468,944 | +376,726 | +12.2% | $72.5M | 2.6% | $20.9 |
| Q2 2021 | 3,092,218 | 0 | — | $54.7M | 2.0% | $17.7 |
| Q1 2021 | 3,092,218 | 0 | — | $75.8M | 3.4% | $24.5 |
| Q4 2020 | 3,092,218 | +450,000 | +17.0% | $104.7M | 5.8% | $33.9 |
| Q3 2020 | 2,642,218 | 0 | — | $66.1M | 4.8% | $25.0 |
| Q2 2020 | 2,642,218 | — | — | $89.1M | 6.7% | $33.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did EcoR1 Capital, LLC first disclose a ORIC position in 13F-HR filings?
EcoR1 Capital, LLC first reported ORIC PHARMACEUTICALS INC (ORIC) on its 13F-HR filing for the period ending 2020-06-30 (Q2 2020). The position has appeared on 24 reported quarters within Pactolio's tracked window.
What was EcoR1 Capital, LLC's most recent quarter-over-quarter share-count change in ORIC?
EcoR1 Capital, LLC held the same 6,728,116 shares of ORIC between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent EcoR1 Capital, LLC's cost basis in ORIC?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.